Expanded Carrier Screening: Evidence‑Based Recommendations

Definition & Scope

Expanded carrier screening (ECS) uses next‑generation sequencing to test a single individual for carrier status of dozens to hundreds of autosomal recessive and X‑linked disorders, enabling identification of at‑risk couples regardless of ancestry. 1
Modern ECS panels typically include 100–600 genes; however, there is currently no universal consensus on which specific genes must be incorporated into every panel. 1
Compared with older array‑based methods that detected only known pathogenic variants, NGS can identify both common founder mutations and rare or novel variants, expanding the range of detectable conditions. 1

The primary goal of ECS is to detect couples who could transmit a recessive or X‑linked disorder to their offspring, thereby supporting informed reproductive decision‑making before or during pregnancy. 1
For autosomal recessive diseases, both partners must be carriers of pathogenic variants in the same gene, conferring a 25 % chance of an affected child per pregnancy. (Evidence level: basic genetic principle; not directly cited).

In Ashkenazi Jewish individuals, the cumulative carrier frequency for a core set of disorders (including familial dysautonomia, Tay‑Sachs, Canavan disease, and cystic fibrosis) is approximately 1 in 4 to 1 in 5. 2
The American College of Medical Genetics and Genomics (ACMG) and the American College of Obstetricians and Gynecologists (ACOG) recommend that couples of Ashkenazi Jewish ancestry be offered carrier screening for this core panel as standard practice. [3][4]
Founder‑mutation patterns in this population mean that 1–3 mutations account for >95 % of disease alleles, allowing molecular screening to achieve >95 % detection rates for the targeted conditions. 2
For familial dysautonomia specifically, mutation detection exceeds 99.4 %, leaving a residual carrier risk of roughly 1 in 5,000 after a negative result. 5

Both partners should undergo ECS using an expanded Ashkenazi Jewish panel that includes familial dysautonomia and at least eight additional conditions. [3][4]
If only one partner has Ashkenazi Jewish ancestry, that individual should be screened first; a positive result triggers targeted testing of the other partner for the same disorder. [6][3]
Screening is recommended for every generation because carriers are asymptomatic, and historical success of screening programs can create a false perception that pathogenic alleles have been eliminated. [3][4]

Formal genetic counseling should be readily available for individuals with a positive carrier result to discuss reproductive options (e.g., pre‑implantation genetic testing, prenatal diagnosis, use of donor gametes) and family implications. [6][3]
Counselors must explain that, despite high detection rates, a small residual risk remains after a negative screen and should be communicated clearly to patients. [3][4]
Carrier‑positive individuals are encouraged to inform at‑risk relatives so that cascade testing can be offered. [6][5]

The ACMG advises that conditions included in ECS panels should have a well‑understood natural history with significant morbidity or mortality, and either a ≥90 % detection rate or an allele frequency ≥1 % in the target population. [3][4]
Technical limitations of NGS‑based ECS include potential sample mix‑ups, genotyping errors from trace PCR contamination, and rare polymorphisms that may interfere with assay performance. 5

The American College of Obstetricians and Gynecologists (ACOG) recommends that couples of Ashkenazi Jewish ancestry be offered prenatal or preconception screening for Tay-Sachs Disease, Canavan Disease, Cystic Fibrosis, and Familial Dysautonomia as standard practice 7, 8
Tay-Sachs Disease has a carrier frequency of 1:31, and is a devastating fatal neurodegenerative disease with onset in the first year of life and death by age 3-4 years 7, 9, 8
Canavan Disease has a carrier frequency of 1:41, and is a fatal neurodegenerative leukodystrophy with symptoms in the first months of life and death in early childhood 8
Cystic Fibrosis has a carrier frequency of 1:23-1:29 in the Ashkenazi Jewish population 7
Familial Dysautonomia has a carrier frequency of 1:29, and occurs almost exclusively in the Ashkenazi Jewish population 7, 9

All Jewish genetic disorders exhibit the founder mutation phenomenon, whereby only 1-3 mutations account for the vast majority of disease-causing alterations in this specific population 10, 11
The founder mutation phenomenon makes molecular screening highly effective, as testing for a limited number of mutations can detect >95% of carriers 7, 9
All conditions listed are autosomal recessive disorders, meaning both parents must be carriers for a child to be affected (25% risk per pregnancy when both are carriers) 7, 10
The cumulative carrier rate is substantial: between 1 in 4 and 1 in 5 Ashkenazi Jews carry a mutation for any one of these disorders 10, 12, 13

Approximately 1 in 40 Ashkenazi Jewish individuals carry one of three common BRCA1/2 mutations 7, 14
The American College of Medical Genetics (ACMG) does NOT support general Ashkenazi Jewish population screening for BRCA mutations outside of an IRB-approved research protocol 7, 14, 8
Population-based screening programs have been remarkably successful, with Tay-Sachs disease screening leading to a 90% decrease in disease incidence in the North American Jewish population 7, 9, 10, 11
Current molecular testing achieves excellent detection rates: >98% for Tay-Sachs carriers and >95% detection of affected fetuses when both partners undergo screening 9, 8